Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
- Status
- WITHDRAWN
- Phase
- PHASE2
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
- Status
- TERMINATED
- Phase
- PHASE3
Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors
- Status
- WITHDRAWN
- Phase
- PHASE2
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
- Status
- TERMINATED
- Phase
- PHASE2
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1